Xantinol Nicotinate: A Comprehensive Reference
1. Identity, Nomenclature, and Chemical Character
Xantinol nicotinate (also spelled xanthinol nicotinate) is a synthetic compound formed from the combination of two pharmacologically active components: xanthinol (a theophylline derivative) and nicotinic acid (niacin, vitamin B3). Xanthinol is a drug prepared from theophylline used as a vasodilator, and it is most often used as the salt with niacin (nicotinic acid), known as xanthinol nicotinate. Pharmacologically, xantinol nicotinate is classified as a vasodilator belonging to the class of purine derivative agents used as peripheral vasodilators.
Its CAS number is 437-74-1 and its molecular formula is C₁₃H₂₁N₅O₄ · C₆H₅NO₂, with a molecular weight of 434.45. The molecular formula is often written in combined form as C₁₉H₂₆N₆O₆ (MW 434.4 g/mol), with FDA UNII 8G60H12X2D. The full IUPAC name is 7-[2-hydroxy-3-[2-hydroxyethyl(methyl)amino]propyl]-1,3-dimethylpurine-2,6-dione;pyridine-3-carboxylic acid.
The compound bears many synonyms and trade names in different regions. It is also known as Complamin, Angioamin, Teonicol, Complamex, Landrina, Sadamine, Stenalgil, Xanidil, Vedrin, Complamin Retard, and Xavin. The International Non-proprietary Name (INN) recognized by the WHO is xantinol nicotinate (with one 'h'), while the United States Adopted Name (USAN) is xanthinol niacinate.
Under the Anatomical Therapeutic Chemical (ATC) classification, xantinol nicotinate is coded C04AD02, placing it within C04AD (purine derivatives), C04A (peripheral vasodilators), C04 (peripheral vasodilators), and the broader C (cardiovascular system) category.
The physical form of the pure compound is a crystalline solid. The melting point of the pure nicotinic acid salt is 180°C, and the substance has a nearly neutral reaction and is very readily soluble in water.
2. Natural Sources and Origin
Xantinol nicotinate is not found as such in nature and has no direct botanical source. It is a fully synthetic pharmaceutical compound produced by chemical condensation of its two constituent moieties. It is a derivative of vitamin B3 (niacin), and can be found in a wide array of dietary supplements. Both constituent parts, however, have natural precedents: nicotinic acid (niacin) is a naturally occurring B-vitamin found in many foods, and xanthinol is a theophylline analogue, while theophylline itself occurs naturally in tea leaves (Camellia sinensis). The compound as a combined salt is entirely the product of organic synthesis.
3. Common Forms and Preparations
Xantinol nicotinate has been commercially manufactured and administered in several pharmaceutical forms:
- Oral tablets and dragées: The most common preparation for systemic use. The adult recommended oral dose reported in some sources is 3 g/day, taken as a tablet by mouth immediately after meals with liquid.
- Slow/sustained-release oral tablets: A slow-release form of xantinol nicotinate (Complamin Retard) has been evaluated in clinical trials for cerebrovascular insufficiency.
- Injectable solution (parenteral): It is administered orally as well as parenterally. The injectable form has been used in acute clinical settings and in research studies.
- Intralesional injection: Intralesional injections of xantinol nicotinate have been used for managing oral submucous fibrosis (OSMF).
- Dietary supplement capsules and powders: The compound can be found in a wide array of dietary supplements.
4. Historical and Traditional Use
Unlike many herbal or botanical supplements, xantinol nicotinate does not have a traditional ethnobotanical history. Its use is entirely rooted in 20th-century pharmaceutical development. The compound appears to have been developed and entered clinical use in Western Europe (primarily German-speaking countries) in the 1960s and 1970s, based on the pharmacological rationale of combining the vasodilatory properties of nicotinic acid with the xanthine (theophylline-like) component.
For some 30 years, xanthinol nicotinate has been on the market for the treatment of impaired brain function, i.e., organic brain syndromes of various etiologies. It was prescribed across Europe, Russia, and parts of Asia for peripheral vascular disorders, cerebrovascular insufficiency, and cognitive symptoms associated with poor cerebral circulation. It was approved as a medication in Canada in 1998, but it has since had its classification as a medication withdrawn.
The drug's use in the Soviet Union and Eastern Europe was well documented: it is referenced in Russian pharmacological literature under the name "ksantinola nikotinat" (ксантинола никотинат). A 1986 paper in the Pharmaceutical Chemistry Journal by Absava reviewed xanthinol nicotinate as a means of improving peripheral and cerebral blood circulation. In this context, it was used clinically for conditions including arteriosclerosis, cerebrovascular insufficiency, memory disorders, and peripheral artery disease, particularly when surgical revascularization was not feasible.
In South and Southeast Asia, especially India, the compound continued to be used as a registered pharmaceutical into the 21st century for peripheral vascular disorders, diabetic angiopathy, and, more recently, as an intralesional treatment for oral submucous fibrosis.
5. Key Constituents and Active Compounds
Xantinol nicotinate is itself a single chemical compound — a 1:1 salt of xanthinol (the theophylline-derived moiety) and nicotinic acid (niacin). Its pharmacological activity is attributable to both of these parent components, acting synergistically.
5.1 Nicotinic Acid (Niacin) Component
Xantinol nicotinate is one of the most potent forms of niacin (B3) which easily passes through the cell membrane, and its general properties are similar to those of nicotinic acid to which it is slowly hydrolysed. In a study by Cheng et al., the vasodilating effect of nicotinic acid was found to be due to increased synthesis and secretion of prostaglandin D2, a type of prostacyclin, in the serum. Prostaglandin D2 directly stimulates vasodilation. Nicotinic acid also increases the release of nitric oxide, another endogenous vasodilator.
5.2 Xanthinol (Theophylline Derivative) Component
Nicotinic acid is a well-known vasodilating agent and xanthinol, a theophylline derivative, enhances its actions. Xanthinol enhances the physiological response to prostaglandin D2 and nitric oxide, increasing the action of their secondary messengers.
The positively charged xanthinol ion is thought to help transport the nicotinic acid into the cell since nicotinic acid cannot freely diffuse through the cell membrane. The mechanism of action is thought to be related to its influence on cell metabolism through the nucleotides NAD and NADP. Nicotinic acid also serves as a coenzyme for proteins involved in tissue respiration (Embden–Meyerhof and citrate cycle).
6. Mechanisms of Action
The compound operates through multiple, complementary pharmacological mechanisms:
6.1 Vasodilation via Phosphodiesterase Inhibition and cAMP Elevation
The theophylline-derived xanthinol component contributes to the drug's overall effect by inhibiting phosphodiesterase enzymes. This inhibition results in an increased concentration of cyclic adenosine monophosphate (cAMP) within vascular smooth muscles, which aids in promoting vasodilation. Through the relaxation of smooth muscles, inhibition of phosphodiesterase, and increased levels of cAMP, it effectively improves blood flow and oxygen delivery to tissues.
6.2 Microcirculation Enhancement and Blood Rheology
Nutritive microcirculation is enhanced by increasing erythrocyte elasticity, improving the flow properties of the blood, and reducing peripheral resistance, while simultaneously improving cardiac function. Xanthinol nicotinate expands blood vessels, improves blood rheology, and reduces peripheral vascular resistance.
6.3 Fibrinolytic and Antiplatelet Activity
Xanthinol nicotinate was found to be fibrinolytic by two mechanisms: reduction of fibrinogen levels and increase in tissue plasminogen activators, which dissolve clots. In patients with peripheral arterial obliterative disease, xanthinol nicotinate was found to have anti-platelet and thrombolytic actions accompanied by an increase in the release of nitric oxide.
6.4 Enhanced Cellular Energy Metabolism
It increases brain glucose metabolism and thus improves brain ATP levels, stimulating memory and concentration while elevating brain energy levels. Xanthinol, as a positively charged ion, may increase the transportation of nicotinic acid into the cell since the latter cannot freely diffuse through the cell membrane.
6.5 Antioxidant Properties
The compound also has antioxidant properties, which help to reduce oxidative stress and protect cells from damage caused by free radicals. This adds another layer of benefit, as oxidative stress is a contributing factor in many chronic diseases, including cardiovascular and neurodegenerative disorders.
6.6 Vascular Smooth Muscle Cell Proliferation Inhibition
In vitro research (not human clinical evidence) has examined an additional mechanism. Vascular smooth muscle cell proliferation is a key event in the development of hypertension, restenosis, and other cardiac disorders, and inhibition of this proliferation could lead to better prevention and treatment. A study investigated the effects and mechanisms of different concentrations of xanthinol nicotinate on human umbilical artery smooth muscle cell (HUASMC) proliferation in vitro. This line of investigation remains at the laboratory stage and has not been translated to human clinical outcomes.
7. Scientific Evidence by Area of Use
7.1 Peripheral Vascular Disease and Intermittent Claudication
This is the most extensively studied clinical application of xantinol nicotinate.
Double-blind controlled trial (Davis & Rozov, 1975): In a double-blind control of xanthinol nicotinate ('Complamin'; 'Complamex') in patients with severe progressive obliterative vascular disease, 25 of 33 patients who completed the trial were helped significantly by the drug, as shown by both clinical and laboratory findings. Placebo helped in 4 of 33 patients. The difference was significant (p < 0.001). Results of follow-up for 6 to 30 months were available in 18 patients; 14 of these still had appreciable help from the drug, which was continued in maintenance doses. Three of 6 diabetics were no longer helped after 6 months, and only 3 of a total of 7 patients under the age of 50 were helped. Xanthinol nicotinate reduced whole-blood viscosity and cholesterol and fibrinogen in about half of the patients helped.
Open-label observational study (Sharma et al.): A study published in the Journal of Advanced Medical and Pharmaceutical Sciences examined 350 patients with peripheral vascular disease treated with xanthinol nicotinate. Out of 350 patients, 341 cases (97.5%) experienced claudication pain, and following treatment, 307 cases (87.9%) reported some relief and improved sense of well-being. Among 216 cases (61.7%) presenting with rest pain, 174 cases (49.8%) achieved relief with reduced analgesic usage. This study lacked a placebo control group and randomization, significantly limiting its interpretive value.
Evidence strength: The double-blind trial provides moderate-quality controlled evidence of benefit in obliterative peripheral vascular disease. The observational study supports symptomatic benefit but cannot establish causation. Overall evidence is limited by small sample sizes, older study designs, and the absence of modern endpoints (e.g., ankle-brachial index, walking distance). The body of evidence is rated as preliminary to moderate by contemporary standards.
7.2 Cerebrovascular Insufficiency and Cognitive Function
Double-blind memory study (Loriaux et al., 1985): The treatment effect of nicotinic acid and xanthinol nicotinate on human memory was compared with placebo in 96 healthy subjects: 43 young (35–45 years), 30 middle-aged (55–65 years), and 23 older (75–85 years). Pre- and post-treatment scores were measured on a battery of memory tasks, covering sensory register, short-term memory, and long-term memory. The treatment regime was one dragée three times daily for 8 weeks. The administration of xanthinol nicotinate (500 mg, containing 141.7 mg nicotinic acid), nicotinic acid (141.7 mg), and placebo (lactose) was double-blind. Nicotinic acid treatment resulted in improvement of sensory register and short-term memory, while xanthinol nicotinate improved sensory register, short-term memory, and long-term memory. In comparison with placebo, both active compounds yielded improvements of 10–40%, depending on type of task. Treatment effects of nicotinic acid were predominantly found in the young and middle-aged, whereas treatment effects of xanthinol nicotinate were predominantly found in the old. These results are interpreted by the supposed activity of nicotinic acid at the cell membrane, improving neuronal transmission, and of xanthinol nicotinate inside the cell, enhancing cell metabolism and oxygen supply in the brain.
Double-blind trial in cerebrovascular insufficiency (Brückner & Jansen, 1979): A psychometric double-blind trial with a slow-release form of xantinol nicotinate was conducted for the therapy of cerebrovascular insufficiency. Full details of this trial are indexed in the Cochrane Central Register of Controlled Trials.
Dementia: Controlled double-blind phase-III clinical trials have shown that xantinol nicotinate is also an effective drug in the treatment of dementia. However, these studies are older and have not been subject to systematic review or meta-analysis by Cochrane or comparable bodies.
Evidence strength: The memory study is methodologically sound (double-blind, placebo-controlled, n=96) but is now decades old and was conducted in healthy volunteers, not patients with diagnosed dementia or cognitive disease. Results are intriguing, particularly the preferential effect in older subjects, but the evidence is preliminary by modern standards. No large randomized controlled trials or systematic reviews focusing specifically on xantinol nicotinate for cognitive outcomes have been identified.
7.3 Lipid-Lowering Effects (Hyperlipoproteinaemia)
Type V hyperlipoproteinaemia study: The effect of xantinol-nicotinate (50 mg/kg body weight) on serum lipids and lipoproteins was tested in 16 outpatients with primary type V hyperlipoproteinaemia. The lipids and lipoproteins were measured before treatment, during a three-week period of drug administration, and ten days after it had been stopped. There were no side effects such as flushing or gastritis, and no notable reduction of weight. Each serum-lipid fraction (triglycerides, non-esterified fatty acids, phospholipids, ester-cholesterol, and free cholesterol) decreased significantly, regaining the initial values ten days after the drug had been stopped.
Combination therapy for type II hyperlipoproteinaemia: A low-dose combination of Complamin® Retard (1 g three times daily) and cholestyramine (4 g twice daily) was compared with each agent alone in serial open trials without dietary restriction using type IIa and IIb hyperlipoproteinaemic patients. Complamin alone produced decreases in LDL and VLDL cholesterol concentrations of up to 20%, whereas cholestyramine alone produced only a modest reduction in LDL of up to 15%. The combination produced marked, progressive reductions in total cholesterol (up to 35%) and LDL (up to 40%); reductions in VLDL (up to 45%), total triglyceride (up to 60%), and free fatty acids (up to 60%) were found only in type IIb patients.
Non-esterified fatty acids in hyperlipoproteinaemia: Treatment with xantinol-nicotinate at 50 mg/kg body weight produced a substantial decrease in total cholesterol concentrations in patients, and it was suggested that the constant decrease in NEFA (non-esterified fatty acids) induced by XN treatment might contribute significantly to the lipid-lowering effect of this drug.
Evidence strength: Lipid-lowering studies generally show statistically significant reductions in various lipid fractions. However, most studies are small, older, and non-randomized or open-label. No large randomized controlled trial specifically on xantinol nicotinate's lipid effects meets modern clinical trial standards. Evidence is preliminary to moderate.
7.4 Prevention of Postoperative Thromboembolism
Prospective randomized multicentre trial (Gruber et al., Lancet, 1977): The efficacy of dextran-40 infusions, low-dose heparin, or xantinol-nicotinate administration in preventing postoperative thromboembolic complications was investigated in a prospective, controlled, randomised trial as part of an international multicentre trial. 382 patients over the age of forty years undergoing elective major general surgery were investigated: 100 had a complete protocol in the control, 94 in the heparin, 92 in the dextran, and 32 in the xantinol-nicotinate group. The frequency of isotopic deep-vein thrombosis was 36.0% in the controls, 12.8% in the heparin group, 21.7% in the dextran group, and 40.6% in the xantinol-nicotinate group. The difference between the controls and the heparin group was highly significant, and between the control and dextran group probably significant. Notably, xantinol nicotinate did not demonstrate significant superiority over the control group for deep-vein thrombosis prevention in this trial, and the xantinol-nicotinate group was the smallest (n=32), limiting conclusions. This study has been indexed in the Cochrane Library and referenced in systematic reviews of venous thromboembolism prevention.
Evidence strength: This trial, published in the Lancet, is the highest-quality controlled evidence regarding thromboembolism prevention. The results do not support xantinol nicotinate as effective prophylaxis against deep-vein thrombosis in a surgical setting; it was inferior to both low-dose heparin and dextran-40 on the primary isotopic endpoint.
7.5 Leg Ulcers Associated with Haemoglobinopathies
Double-blind crossover trial (PubMed PMID 540521): The therapeutic role of xanthinol nicotinate, with its potent action on the peripheral circulation, in promoting healing of leg ulcers when added to conservative measures of ulcer treatment in adult beta-thalassaemia major and sickle cell thalassaemia, was evaluated in a double-blind crossover trial in 16 patients suffering from multiple leg ulcers. Xanthinol nicotinate or placebo was administered in a daily dose of 8 tablets (2400 mg) for 10 weeks. Comparison of the treatment results revealed a statistically significant higher rate of complete ulcer healing during xanthinol nicotinate therapy (p < 0.01). Apart from a low incidence of generalised itching and flushing at the start of the trial, xanthinol nicotinate was well tolerated in the prescribed dose.
Evidence strength: This is a double-blind crossover trial showing statistically significant benefit, though with a very small sample size (n=16) in a specific, narrowly defined population (haemoglobinopathy-associated leg ulcers). The evidence is intriguing but insufficient to generalize to other ulcer aetiologies or larger populations.
7.6 Oral Submucous Fibrosis (OSMF)
Randomised parallel clinical study (Singh et al., 2016, PMC5121800): This parallel, prospective, clinical study included 60 patients clinically diagnosed with oral submucous fibrosis divided into two groups. Group I patients were subjected to intralesional xantinol nicotinate injections bi-weekly for a period of four months, while Group II patients were given intralesional saline injections biweekly for four months. At each visit, parameters like increase in interincisal distance, cheek flexibility, tongue protrusion, and relief from burning sensation were measured. At the end of four months, in Group I there was an increase in mean values of interincisal distance, cheek flexibility, and tongue protrusion (p < 0.001). Xantinol nicotinate, when injected intralesionally in OSMF patients, not only provides relief from burning sensation but also results in increased mouth opening, tongue protrusion, and cheek flexibility.
A 2020 systematic review of medicinal management of OSMF over a decade, published in PMC, noted that a single study evaluated intralesional xantinol nicotinate compared with placebo, confirming the limited but emerging evidence base in this indication.
Evidence strength: The OSMF study provides prospective, randomized controlled evidence with a placebo comparator, showing significant benefit on key functional outcomes. However, it is a single-centre study with a moderate sample size and no long-term follow-up. Evidence is preliminary but promising for this specific indication.
7.7 Tumour Perfusion and Radiosensitization
A preclinical (animal model) study explored a novel application of xanthinol nicotinate. The hypothesis was tested that the vasoactive agent xanthinol nicotinate could be an important modulator of tumour perfusion and oxygenation. Using functional non-invasive techniques (in vivo EPR oximetry and dynamic contrast-enhanced MRI), the investigators defined a time window in which tumour oxygenation, flow, and permeability were significantly increased in a mouse tumour model. As a consequence of the alleviation of tumour hypoxia, xanthinol nicotinate was able to radiosensitize the tumours when applying 10 Gy of X-rays during the reoxygenation of the tumours (enhancement in radiation response of 1.4).
Evidence strength: This is animal/preclinical data only. No human clinical trials on xanthinol nicotinate as a radiosensitizer or chemotherapy adjunct have been identified in the published literature. Evidence is purely exploratory.
8. Body Systems and Health Areas
Based on the published evidence, xantinol nicotinate has been investigated or applied in the following body systems and health areas:
- Cardiovascular / peripheral vascular system: Xanthinol is indicated to improve cerebrovascular and peripheral vascular disorders as well as hyperlipidemias. Clinical applications have included obliterative peripheral artery disease, intermittent claudication, arteriosclerosis, endarteritis obliterans, and diabetic angiopathy.
- Cerebrovascular system: It has been employed for its vasodilator action in treatment of cerebral and peripheral vascular disorders.
- Central nervous system / cognitive function: It increases brain glucose metabolism and thus improves brain ATP levels, stimulating memory and concentration while elevating brain energy levels.
- Haematological / coagulation system: Via fibrinolytic and antiplatelet effects — reduction of fibrinogen, activation of tissue plasminogen activators, and nitric oxide release.
- Lipid metabolism: Reduction of total cholesterol, LDL, VLDL, triglycerides, and non-esterified fatty acids in patients with hyperlipoproteinaemia.
- Oral and mucosal tissues: Intralesional use in oral submucous fibrosis, a potentially malignant fibrosing disorder of the oral mucosa.
- Wound healing / skin: Improvement of leg ulcer healing in haemoglobinopathy patients, via enhanced peripheral microcirculation.
- Experimental oncology: Preclinical evidence only, for tumour perfusion modulation and radiosensitization.
9. Dosage Forms and Dosages Reported in Studies
The following dosages are reported only as found in primary research sources and pharmacological references:
- Adult oral dose reported in drug information: 3 g/day.
- In the memory double-blind study, the treatment regime was one dragée (500 mg xanthinol nicotinate, containing 141.7 mg nicotinic acid) three times daily for 8 weeks.
- In the haemoglobinopathy leg ulcer trial, xanthinol nicotinate or placebo was administered in a daily dose of 8 tablets (2400 mg) for 10 weeks.
- In the type V hyperlipoproteinaemia study, xantinol-nicotinate was administered at 50 mg/kg body weight.
- In the combination lipid-lowering trial, Complamin® Retard 1 g three times daily (total 3 g/day) was combined with cholestyramine 4 g twice daily.
- In the OSMF intralesional trial, Group I patients received intralesional xantinol nicotinate injections bi-weekly for a period of four months.
- In the in vitro vascular smooth muscle cell study, concentrations of XN tested were 0, 2.76, 27.6, or 276 µM.
10. Safety Considerations and Interactions
10.1 Known and Reported Adverse Effects
The adverse effect profile of xantinol nicotinate broadly mirrors that of nicotinic acid (niacin), with additional effects from the xanthinol moiety. The most commonly reported adverse effect across clinical studies is flushing.
Side effects were common in clinical use, particularly a severe prolonged flush shortly after taking a dose of the drug; many patients who were helped by it accepted this side-effect if it occurred.
Severe toxicoderma has been reported with xanthinol nicotinate and confirmed by a provocation test. Flushing is claimed to be less frequent with xanthinol nicotinate than with nicotinic acid, but has nevertheless been repeatedly observed, and its other adverse effects are likely to be the same as those of nicotinic acid. (Source: Meyler's Side Effects of Drugs, 15th edition, via ScienceDirect.)
Reported side effects include headache, flushing (feeling of warmth in the face, ears, neck and trunk), dizziness, palpitations, stomach upset, nausea, vomiting, dry skin, skin rash, excess thirst, and breathlessness.
In the haemoglobinopathy ulcer trial, apart from a low incidence of generalised itching and flushing at the start of the trial, xanthinol nicotinate was well tolerated in the prescribed dose.
10.2 Hepatic Considerations
As a niacin derivative, hepatic effects must be considered, though there are no large-scale hepatotoxicity studies specific to xantinol nicotinate. There have been several reports of hepatotoxicity with modified-release formulations of nicotinic acid, and other adverse effects include hepatotoxicity (apparently a dose-related direct toxic effect), hyperglycaemia, and hyperuricaemia. Caution is advised when prescribing xantinol nicotinate to individuals with liver or kidney impairment, as these organs play a crucial role in metabolizing and excreting the drug.
10.3 Contraindications Documented in Clinical Literature
Contraindications include conditions like severe hypotension, recent myocardial infarction, and active peptic ulcer disease. Patients with a history of hypersensitivity to niacin or theophylline should avoid this medication.
Documented contraindications from drug information sources include acute haemorrhage, acute myocardial infarction, decompensated cardiac insufficiency, congestive heart diseases, and severe hypotension.
Special caution was indicated in the use of the drug in patients who have ischaemic heart disease in addition to their peripheral arterial disease, as noted in the Davis & Rozov double-blind trial.
10.4 Drug Interactions
Because xantinol nicotinate combines a theophylline analogue and niacin, interactions relevant to each parent compound may apply:
- Antihypertensive agents: Alcohol should not be consumed with xanthinol nicotinate as it may increase the risk of low blood pressure. By extension, co-administration with other vasodilators or antihypertensive drugs may produce additive hypotension.
- Anticoagulants / antiplatelet drugs: Given the compound's documented fibrinolytic and antiplatelet actions, concurrent use with anticoagulants (e.g., warfarin, heparin) or antiplatelet agents may theoretically increase bleeding risk, though this has not been formally studied.
- Hypersensitivity history: Patients with a history of hypersensitivity to niacin or theophylline should avoid this medication.
10.5 Regulatory and Market Status
Xanthinol was approved as a drug in 1998 in Canada; its status is now cancelled post-marketing. It is a very potent water-soluble derivative of niacin that can be found in dietary supplements. In numerous other countries, including India and several European nations, it has been available as a pharmaceutical product. Its dietary supplement availability in markets where its pharmaceutical status is not maintained means consumers may access it without clinical oversight.
11. Overall Evidence Assessment
Xantinol nicotinate has an established pharmacological rationale as a dual-action vasodilator and niacin derivative. The clinical evidence supporting its use is predominantly from the 1970s and 1980s, consisting of small controlled trials, open observational studies, and some double-blind controlled research. In the most rigorously designed studies — the double-blind peripheral vascular disease trial, the memory study, and the leg ulcer crossover trial — statistically significant benefits were observed. However, these studies are limited by small sample sizes, older methodology, and the absence of modern clinical endpoints. No Cochrane systematic review specific to xantinol nicotinate has been published. A 2016 randomized controlled trial on oral submucous fibrosis represents among the most recent controlled human evidence.
The compound is not currently recognized as a first-line or guideline-recommended therapy for any condition in major Western clinical practice guidelines. Its use as a dietary supplement ingredient is unregulated in many jurisdictions, and the evidence base does not yet support efficacy claims in healthy populations.
References
Go back